Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Long-Term Deferred Tax (2018 - 2025)

Anika Therapeutics (ANIK) has disclosed Long-Term Deferred Tax for 9 consecutive years, with $1.3 million as the latest value for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 8.33% to $1.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 million through Dec 2025, up 8.33% year-over-year, with the annual reading at $1.3 million for FY2025, 8.33% up from the prior year.
  • Long-Term Deferred Tax for Q4 2025 was $1.3 million at Anika Therapeutics, up from $1.3 million in the prior quarter.
  • The five-year high for Long-Term Deferred Tax was $1.5 million in Q1 2023, with the low at $1.2 million in Q4 2024.
  • Average Long-Term Deferred Tax over 4 years is $1.4 million, with a median of $1.4 million recorded in 2024.
  • The sharpest move saw Long-Term Deferred Tax dropped 20.95% in 2024, then grew 8.33% in 2025.
  • Over 4 years, Long-Term Deferred Tax stood at $1.4 million in 2022, then grew by 2.76% to $1.5 million in 2023, then decreased by 20.95% to $1.2 million in 2024, then grew by 8.33% to $1.3 million in 2025.
  • According to Business Quant data, Long-Term Deferred Tax over the past three periods came in at $1.3 million, $1.3 million, and $1.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.